About Converge Bio
Converge Bio is a company based in Wilmington (United States) founded in 2024. It operates as a AI-as-a-Service, and Managed Services. Converge Bio has raised $30.5 million across 2 funding rounds from investors including TLV Partners, Bessemer Venture Partners and Vintage Investment Partners. Converge Bio offers products and services including Converge Computational Lab, Antibody Design, Bio Manufacturing, and Virtual Cell Simulation. Converge Bio operates in a competitive market with competitors including Fauna Bio, BeaconCure, Predxbio, Lila Sciences and Humaneva Group, among others.
- Headquarter Wilmington, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$30.5 M (USD)
in 2 rounds
-
Latest Funding Round
$25 M (USD), Series A
Jan 13, 2026
-
Investors
TLV Partners
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Converge Bio
Converge Bio offers a comprehensive portfolio of products and services, including Converge Computational Lab, Antibody Design, Bio Manufacturing, and Virtual Cell Simulation. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
GenAI platform for accelerating drug development processes.
AI-driven antibody discovery and optimization for therapies.
Generative AI used to maximize protein yields.
Simulates cellular responses for treatment outcome predictions.
Funding Insights of Converge Bio
Converge Bio has successfully raised a total of $30.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $25 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $25.0M
-
First Round
First Round
(20 Nov 2024)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Series A - Converge Bio | Valuation | Bessemer Venture Partners | |
| Nov, 2024 | Amount | Seed - Converge Bio | Valuation | TLV Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Converge Bio
Converge Bio has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include TLV Partners, Bessemer Venture Partners and Vintage Investment Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm investing in early stage startups in Israel & the US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Converge Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Converge Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Converge Bio Comparisons
Competitors of Converge Bio
Converge Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Fauna Bio, BeaconCure, Predxbio, Lila Sciences and Humaneva Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Animal genomics is applied to healthcare advancements by Fauna Bio.
|
|
| domain | founded_year | HQ Location |
Data analytics and validation software for regulatory submission in the healthcare sector
|
|
| domain | founded_year | HQ Location |
AI-based drug discovery and clinical services are provided for biopharma.
|
|
| domain | founded_year | HQ Location |
AI-powered platforms for autonomous scientific research are developed.
|
|
| domain | founded_year | HQ Location |
Provider of clinical research data services for oncology & other therapeutic areas
|
|
| domain | founded_year | HQ Location |
AI-powered diligence and valuation for drug assets are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Converge Bio
When was Converge Bio founded?
Converge Bio was founded in 2024.
Where is Converge Bio located?
Converge Bio is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Is Converge Bio a funded company?
Converge Bio is a funded company, having raised a total of $30.5M across 2 funding rounds to date. The company's 1st funding round was a Seed of $5.5M, raised on Nov 20, 2024.
What does Converge Bio do?
Converge Bio is engaged in transforming biotechnology through GenAI-powered innovations. Drug development is accelerated by solutions in discovery, molecule design, and manufacturing. The Converge Computational Lab is utilized to engineer precise antibodies, maximize protein yields, and predict cellular responses. Integration is seamlessly built into operations, ensuring data privacy and full control over creations. The biotech sector is primarily served, with a focus on creating therapies for the future.
Who are the top competitors of Converge Bio?
Converge Bio's top competitors include Fauna Bio, Predxbio and Lila Sciences.
What products or services does Converge Bio offer?
Converge Bio offers Converge Computational Lab, Antibody Design, Bio Manufacturing, and Virtual Cell Simulation.
Who are Converge Bio's investors?
Converge Bio has 4 investors. Key investors include TLV Partners, Bessemer Venture Partners, Vintage Investment Partners, and Saras Capital.